Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

A. Menarini Diagnostics S.r.l.

A. Menarini Diagnostics S.r.l. is fully committed to developing high tech diagnostics instruments and reagents to imp... read more Featured Products: More products

Download Mobile App





Menarini Diagnostics Launches New SARS-CoV-2 Antigen Test That Also Measures Viral Load

By LabMedica International staff writers
Posted on 22 Sep 2020
A new COVID-19 test from A. More...
Menarini Diagnostics (Florence, Italy) to detect the presence of antigens can not only determine whether a patient is positive for COVID-19, but also provide an indication of the viral load, allowing the most infectious and most at-risk patients to be identified immediately.

These tests are unlike molecular biology tests because, although they also use nasopharyngeal swabs to take the sample, antigen tests do not search for the genetic material of the virus. Instead, they check for the presence of antigens and, therefore, for potential infection by searching for specific viral proteins. They do this through instruments which are easy to transport and use, quicker and cheaper and with equally reliable results. One such instrument is the AFIAS Point-of-Care platform distributed by A. Menarini Diagnostics in Italy and other European countries. This device can be used in decentralized settings not directly connected to the analysis laboratory, such as emergency rooms, airports, or other situations where time or patient convenience matter.

Two models are currently available: AFIAS 1, which can handle one test at a time, and AFIAS 6, which allows six samples to be examined at the same time. Moreover, the same platform can also be used to perform serological antibody tests, detecting the presence and measuring the quantity of IgM and IgG antibodies in a patient's blood sample. Using AFIAS 6, for example, three patients can have both serological antibody and antigen tests done at the same time, getting their results in just 12 minutes.

"It is vitally important to provide reliable tests allowing large-scale screening and the rapid detection of positive cases in order to contain the spread of COVID-19," said Fabio Piazzalunga, Global Head of A. Menarini Diagnostics. "Ultimately, our lives and economies will be increasingly reliant on the availability and efficiency of these diagnostic tools."

Related Links:
A. Menarini Diagnostics


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: iStock

AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health

Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.